Context Therapeutics (CNTX) Competitors $0.82 -0.01 (-0.93%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.32%) As of 09/5/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. LRMR, OCGN, GLUE, DMAC, SCPH, CTNM, FDMT, CAPR, FHTX, and LFCRShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Larimar Therapeutics (LRMR), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), DiaMedica Therapeutics (DMAC), scPharmaceuticals (SCPH), Contineum Therapeutics (CTNM), 4D Molecular Therapeutics (FDMT), Capricor Therapeutics (CAPR), Foghorn Therapeutics (FHTX), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Its Competitors Larimar Therapeutics Ocugen Monte Rosa Therapeutics DiaMedica Therapeutics scPharmaceuticals Contineum Therapeutics 4D Molecular Therapeutics Capricor Therapeutics Foghorn Therapeutics Lifecore Biomedical Larimar Therapeutics (NASDAQ:LRMR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do institutionals and insiders hold more shares of LRMR or CNTX? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate LRMR or CNTX? Larimar Therapeutics presently has a consensus price target of $18.43, suggesting a potential upside of 367.73%. Context Therapeutics has a consensus price target of $5.25, suggesting a potential upside of 539.93%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Larimar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media refer more to LRMR or CNTX? In the previous week, Context Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 2 mentions for Context Therapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.67 beat Context Therapeutics' score of 1.33 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Context Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LRMR or CNTX more profitable? Context Therapeutics' return on equity of -38.80% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -62.92% -53.98% Context Therapeutics N/A -38.80%-37.53% Which has better earnings & valuation, LRMR or CNTX? Larimar Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.56-2.53Context TherapeuticsN/AN/A-$26.73M-$0.36-2.28 Which has more volatility & risk, LRMR or CNTX? Larimar Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. SummaryContext Therapeutics beats Larimar Therapeutics on 10 of the 14 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.28M$2.56B$5.77B$9.91BDividend YieldN/A50.34%6.71%4.52%P/E Ratio-2.2823.0375.5426.08Price / SalesN/A569.11480.4288.30Price / CashN/A167.8736.9659.01Price / Book0.655.5011.446.09Net Income-$26.73M$32.95M$3.28B$266.14M7 Day Performance-2.33%2.86%0.96%0.35%1 Month Performance17.37%8.61%7.83%4.42%1 Year Performance-64.64%1.86%62.64%26.17% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics3.4458 of 5 stars$0.82-0.9%$5.25+539.9%-64.0%$74.28MN/A-2.287Positive NewsLRMRLarimar Therapeutics3.4499 of 5 stars$3.62-7.4%$18.43+409.1%-55.7%$299.66MN/A-2.3230Positive NewsOCGNOcugen1.3474 of 5 stars$1.02-2.9%$6.00+488.2%-12.7%$298.15M$4.05M-5.1080GLUEMonte Rosa Therapeutics2.6366 of 5 stars$4.80-0.6%$15.33+219.4%-17.8%$296.45M$75.62M13.3390News CoverageDMACDiaMedica Therapeutics2.1492 of 5 stars$5.71-2.7%$12.33+116.0%+59.5%$295.14MN/A-8.2820Trending NewsAnalyst DowngradeInsider TradeGap UpSCPHscPharmaceuticals4.2035 of 5 stars$5.50-0.2%$12.00+118.2%+7.3%$293.14M$36.33M-3.0430Short Interest ↑High Trading VolumeCTNMContineum Therapeutics2.7058 of 5 stars$10.45+4.0%$22.75+117.7%-35.2%$293.04M$50M-4.7531News CoverageShort Interest ↑FDMT4D Molecular Therapeutics2.9647 of 5 stars$6.16-0.3%$30.40+393.5%-53.1%$287.69M$40K-1.75120News CoverageCAPRCapricor Therapeutics2.4661 of 5 stars$6.28+0.3%$22.56+259.2%+59.0%$287.10M$22.27M-3.83101FHTXFoghorn Therapeutics2.6894 of 5 stars$5.06+1.0%$10.67+110.8%-28.6%$286.04M$22.60M-4.25120Positive NewsLFCRLifecore Biomedical0.9997 of 5 stars$7.61-0.1%$8.00+5.1%+64.4%$284.67M$128.87M-5.81690Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies LRMR Alternatives OCGN Alternatives GLUE Alternatives DMAC Alternatives SCPH Alternatives CTNM Alternatives FDMT Alternatives CAPR Alternatives FHTX Alternatives LFCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
